Newron to Present at the Jefferies 2017 Healthcare Conference in New York

MILAN & MORRISTOWN, N.J.--()--Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system (CNS) and pain, today announced that Stefan Weber, CEO, will present at the Jefferies 2017 Healthcare Conference in New York, NY on Wednesday, June 7, 2016 at 9:00 a.m. ET.

About Newron Pharmaceuticals
Newron (SIX: NWRN) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system (CNS) and pain. The Company is headquartered in Bresso near Milan, Italy, with a subsidiary in Morristown, NJ, USA. Xadago® (safinamide) has received marketing authorization for the treatment of Parkinson’s disease in the European Union, Switzerland and the USA, and is commercialized by Newron’s partner Zambon. US WorldMeds holds the commercialization rights in the USA. In addition to Xadago® for Parkinson’s disease, Newron has a strong pipeline of promising treatments for rare disease patients at various stages of clinical development, including sarizotan for patients with Rett syndrome and ralfinamide for patients with specific rare pain indications. Newron is also developing Evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia. http://www.newron.com/en.

Contacts

Media
Newron Pharmaceuticals S.p.A.
Stefan Weber, +39 02 6103 46 26
CEO
pr@newron.com
or
UK/Europe
FTI Consulting
Julia Phillips, +44 (0)20 3727 1000
or
Switzerland
IRF Communications
Martin Meier-Pfister, +41 43 244 81 40
or
Germany
MC Services AG
Anne Hennecke, +49 211 52925222
or
USA
LaVoieHealthScience
Beth Kurth, +1 617-374-8800, Ext. 106
or
Investors and Analysts
Stefan Weber, +39 02 6103 46 26
CEO
ir@newron.com
or
UK/Europe
FTI Consulting
Julia Phillips, +44 (0)20 3727 1000
or
Germany
MC Services AG
Anne Hennecke, +49 211 52925222
or
USA
LaVoieHealthScience
Beth Kurth +1 617-374-8800, Ext. 106

Release Summary

Newron today announced that Stefan Weber, CEO, will present at the Jefferies 2017 Healthcare Conference in New York, NY on Wednesday, June 7, 2016 at 9:00 a.m. ET.

Contacts

Media
Newron Pharmaceuticals S.p.A.
Stefan Weber, +39 02 6103 46 26
CEO
pr@newron.com
or
UK/Europe
FTI Consulting
Julia Phillips, +44 (0)20 3727 1000
or
Switzerland
IRF Communications
Martin Meier-Pfister, +41 43 244 81 40
or
Germany
MC Services AG
Anne Hennecke, +49 211 52925222
or
USA
LaVoieHealthScience
Beth Kurth, +1 617-374-8800, Ext. 106
or
Investors and Analysts
Stefan Weber, +39 02 6103 46 26
CEO
ir@newron.com
or
UK/Europe
FTI Consulting
Julia Phillips, +44 (0)20 3727 1000
or
Germany
MC Services AG
Anne Hennecke, +49 211 52925222
or
USA
LaVoieHealthScience
Beth Kurth +1 617-374-8800, Ext. 106